Iron metabolism and related genetic diseases: A cleared land, keeping mysteries, Journal of Hepatology, vol.64, issue.2 ,
DOI : 10.1016/j.jhep.2015.11.009
URL : https://hal.archives-ouvertes.fr/hal-01231421
Iron disorders of genetic origin: a changing world, Trends in Molecular Medicine, vol.17, issue.12, pp.707-720, 2011. ,
DOI : 10.1016/j.molmed.2011.07.004
URL : https://hal.archives-ouvertes.fr/hal-00739428
Diagnosis and treatment of hereditary hemochromatosis: an update, Expert Review of Gastroenterology & Hepatology, vol.7, issue.6, pp.517-547, 2013. ,
DOI : 10.1586/17474124.2013.816114
A novel MHC class I???like gene is mutated in patients with hereditary haemochromatosis, Nature Genetics, vol.88, issue.4, pp.399-408, 1996. ,
DOI : 10.1016/0888-7543(95)80219-C
Hereditary Hemochromatosis, New England Journal of Medicine, vol.358, issue.3, pp.221-251, 2008. ,
DOI : 10.1056/NEJMoa073286
Hemochromatosis, New England Journal of Medicine, vol.369, issue.8, pp.785-791, 2013. ,
DOI : 10.1056/NEJMc1303066
Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene Non- HFE hemochromatosis: pathophysiological and diagnostic aspects, Biochimie. Bardou-Jacquet E Clin. Res. Hepatol. Gastroenterol, vol.8, issue.382, pp.143-54, 2014. ,
The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing dataPubmed ahead of print, Genet. Med. Lancet, vol.10, 2015. ,
Iron therapy in chronic kidney disease: Recent changes, benefits and risks. Blood Rev The pathophysiology of transfusional iron overload, Hematol. Oncol, vol.12, 2015. ,
Iron overload in non-transfusion-dependent thalassemia: a clinical perspective, Blood Reviews, vol.26, issue.1, pp.16-25, 2012. ,
DOI : 10.1016/S0268-960X(12)70006-1
A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload, Journal of Biological Chemistry, vol.276, issue.11, pp.7811-7820, 2001. ,
DOI : 10.1074/jbc.M008923200
Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice, Proceedings of the National Academy of Sciences, vol.98, issue.15, pp.98-8780, 2001. ,
DOI : 10.1073/pnas.151179498
URL : https://hal.archives-ouvertes.fr/inserm-00331349
Systemic Iron Homeostasis, Physiological Reviews, vol.93, issue.4, pp.1721-1762, 2013. ,
DOI : 10.1152/physrev.00008.2013
Identification of erythroferrone as an erythroid regulator of iron metabolism, Nature Genetics, vol.91, issue.7, pp.678-84, 2014. ,
DOI : 10.1002/hep.25615
Erythroferrone contributes to recovery from anemia of inflammation, Blood, vol.124, issue.16, pp.2569-74, 2014. ,
DOI : 10.1182/blood-2014-06-584607
Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity Non-transferrin bound iron: a key role in iron overload and iron toxicity, Br. J. Haematol. Biochim. Biophys. Acta, vol.40, issue.203, pp.255-63, 1978. ,
Aceruloplasminemia, Int. Rev. Neurobiol, vol.110, pp.125-51, 2013. ,
DOI : 10.1016/B978-0-12-410502-7.00007-7
Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin, The EMBO Journal, vol.21, issue.12, pp.2823-312, 2007. ,
DOI : 10.1038/sj.emboj.7601735
Labile plasma iron in iron overload: redox activity and susceptibility to chelation, Blood, vol.102, issue.7, pp.2670-2677, 2003. ,
DOI : 10.1182/blood-2003-03-0807
Redox active plasma iron in C282Y/C282Y hemochromatosis, Blood, vol.105, issue.11, pp.4527-4558, 2005. ,
DOI : 10.1182/blood-2004-09-3468
LPI-labile plasma iron in iron overload, Best Practice & Research Clinical Haematology, vol.18, issue.2, pp.277-87, 2005. ,
DOI : 10.1016/j.beha.2004.10.003
Labile iron in cells and body fluids: physiology, pathology, and pharmacology, Frontiers in Pharmacology, vol.105, issue.e79870, 2014. ,
DOI : 10.1182/blood-2004-06-2226
The liver: conductor of systemic iron balance, Blood, vol.123, issue.2, pp.168-76, 2003. ,
DOI : 10.1182/blood-2013-06-427757
A new mutation in the hepcidin promoter impairs its BMP response and contributes to a severe phenotype in HFE related hemochromatosis, Haematologica, vol.94, issue.5, pp.720-724, 2009. ,
DOI : 10.3324/haematol.2008.001784
URL : https://hal.archives-ouvertes.fr/inserm-00372237
Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload, Hepatology, p.2015, 1932. ,
Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis, J.Hepatol. Hum. Mol. Genet, vol.57, issue.2314, pp.1319-1344, 2012. ,
Hyperferritin??mies non h??mochromatosiques, Gastroent??rologie Clinique et Biologique, vol.33, issue.4, pp.323-329, 2009. ,
DOI : 10.1016/j.gcb.2009.02.009
Hemophagocytic lymphohistiocytosis in adults: Diagnosis and treatment, Joint Bone Spine, vol.79, issue.4, pp.356-61, 2012. ,
DOI : 10.1016/j.jbspin.2011.10.015
Dysmetabolic iron overload syndrome: a systemic disease?], Presse Med, vol.436, pp.625-632, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01147025
Iron-chelating therapy for transfusional iron overload, N. Engl. J ,
Second International Round Robin for the Quantification of Serum Non-Transferrin-Bound Iron and Labile Plasma Iron in Patients with Iron- Overload Disorders. Haematologica Second round robin for plasma hepcidin methods: first steps toward harmonization, Am. J. Hematol, vol.87, issue.10, pp.977-83, 2012. ,
Estimating tissue iron burden: current status and future prospects, British Journal of Haematology, vol.147, issue.1, pp.15-28, 2015. ,
DOI : 10.1111/bjh.13374
Impact of iron assessment by MRI. Hematology / the Education Program of the Am Soc Hematol Educ Program, pp.443-50, 2011. ,
Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance, Blood, vol.105, issue.2, pp.855-61, 2005. ,
DOI : 10.1182/blood-2004-01-0177
Non-invasive assessment of hepatic iron stores by MRI, The Lancet, vol.363, issue.9406, pp.357-62, 2004. ,
DOI : 10.1016/S0140-6736(04)15436-6
EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH), European Journal of Human Genetics, vol.47, issue.4, pp.83-90, 2015. ,
DOI : 10.1002/hep.24330
URL : https://hal.archives-ouvertes.fr/hal-01187326
Pathology of hepatic iron overload. Semin liver Dis, pp.260-71, 2011. ,
Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis, Liver International, vol.57, issue.6, pp.1731-1739, 2015. ,
DOI : 10.1111/liv.12762
URL : https://hal.archives-ouvertes.fr/hal-01134727
Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders, Journal of Hepatology, vol.63, issue.5, 1949. ,
DOI : 10.1016/j.jhep.2015.06.027
Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major, New England Journal of Medicine, vol.343, issue.5, pp.327-358, 2000. ,
DOI : 10.1056/NEJM200008033430503
Treatment of nongout joint deposition diseases: an update Haemochromatosis: The bone and the joint, Arthritis, vol.2014, pp.375202-53, 2014. ,
Iron chelation, Current Opinion in Hematology, vol.21, issue.3, pp.179-85, 2014. ,
DOI : 10.1097/MOH.0000000000000031
Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major Improvement in liver pathology of patients with betathalassemia treated with deferasirox for at least 3 years HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox, Front. Pharmacol. Gastroenterology. Acta Haematol, vol.5, issue.1244, pp.217-561202, 2010. ,
Manipulation of the hepcidin pathway for therapeutic purposes, Haematologica, vol.98, issue.11 ,
DOI : 10.3324/haematol.2013.084624
Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis, Blood, vol.120, issue.18, pp.3829-3865, 2012. ,
DOI : 10.1182/blood-2012-07-440743
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload, Blood, vol.125, issue.25, pp.3868-77, 2015. ,
DOI : 10.1182/blood-2014-07-586677
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients Reversal of hemochromatosis by apotransferrin in non-transfused and transfused Hbbth3/+ (heterozygous B1/B2 globin gene deletion) mice, Eur. J. Haematol. Haematologica, vol.62, issue.1005, pp.611-633, 2015. ,
RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of ??-thalassemia intermedia, American Journal of Hematology, vol.122, issue.4, pp.310-313, 2015. ,
DOI : 10.1002/ajh.23934
Protein Antioxidants in Thalassemia, Adv. Clini.Chem, vol.60, pp.85-128, 2013. ,
DOI : 10.1016/B978-0-12-407681-5.00003-9
A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in ??-thalassemia major patients receiving desferrioxamine, European Journal of Haematology, vol.2010, issue.3, pp.202-211, 2013. ,
DOI : 10.1111/ejh.12061
Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload. Liver Int, 2015. ,